SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

BACKGROUND: Scaling SARS-CoV-2 testing to meet demands of safe reopenings continues to be plagued by assay costs and supply chain shortages. In response, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). METHODS: We simplifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogels, Chantal B.F., Watkins, Anne E., Harden, Christina A., Brackney, Doug E., Shafer, Jared, Wang, Jianhui, Caraballo, César, Kalinich, Chaney C., Ott, Isabel M., Fauver, Joseph R., Kudo, Eriko, Lu, Peiwen, Venkataraman, Arvind, Tokuyama, Maria, Moore, Adam J., Muenker, M. Catherine, Casanovas-Massana, Arnau, Fournier, John, Bermejo, Santos, Campbell, Melissa, Datta, Rupak, Nelson, Allison, Dela Cruz, Charles S., Ko, Albert I., Iwasaki, Akiko, Krumholz, Harlan M., Matheus, J.D., Hui, Pei, Liu, Chen, Farhadian, Shelli F., Sikka, Robby, Wyllie, Anne L., Grubaugh, Nathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Clinical and Translational Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836249/
https://www.ncbi.nlm.nih.gov/pubmed/33521748
http://dx.doi.org/10.1016/j.medj.2020.12.010

Ejemplares similares

Ejemplares similares